Synthetic 1,4-anthracenediones, which block nucleoside transport and induce DNA fragmentation, retain their cytotoxic efficacy in daunorubicin-resistant HL-60 cell lines

Anti-Cancer Drugs

Volumn 12, Issue 10, 2001, Pages 807-819

  Wu, Mingfu ^a   Wang, Buna ^a   Perchellet, Elisabeth M ^a   Sperfslage, Bonnie J ^a   Stephany, Heidi A ^a   Hua, Duy H ^a   Perchellet, Jean Pierre ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

1,4 Anthracenediones; DNA synthesis and fragmentation; Nucleoside transport; Tumor cell growth and viability; Wild type and multidrug resistant HL 60 cells

Indexed keywords

6,7 DICHLORO 1,4 ANTHRACENEDIONE; ANTHRACENE 1,4 DIONE; ANTHRACENE DERIVATIVE; ANTINEOPLASTIC AGENT; DNA FRAGMENT; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

AMINO ACID TRANSPORT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL STRAIN HL 60; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA CLEAVAGE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIDRUG RESISTANCE; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; R FACTOR; TUMOR GROWTH;

ANTHRAQUINONES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL SURVIVAL; DAUNORUBICIN; DNA; DNA FRAGMENTATION; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS; NUCLEOSIDES; P-GLYCOPROTEIN;

EID: 0035217579     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200111000-00004     Document Type: Article

References (60)

1. Bioactivation as a model for drug design bioreductive alkylation
2. Quinone chemistry and toxicity
3. Anthracyclines
4. Quinone toxicity in hepatocytes without oxidative stress
5. Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents
6. 2/M cell cycle arrest and apoptosis
7. DNA topoisomerase poisons as antitumor drugs
8. Adriamycin-enhanced membrane lipid peroxidation in isolated rat nuclei
9. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells
10. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells
11. Bcl-2 and mdr-1 gene expression during doxorubicin- induced apoptosis in murine leukemic P388 and P388/R84 cells
12. 1,4-Anthraquinone: An anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro
13. Effects of nucleoside transport inhibitors on thymidine salvage and the toxicity of nucleoside analogs in mouse bone marrow granulocyte-macrophage progenitor cells
14. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B
15. Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transport
16. Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells
17. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole
18. 1-acid glycoprotein binding
19. Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition
20. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
21. Multidrug resistance in MCF-7 human breast cancer cells is associated with increased expression of nucleoside transporters and altered uptake of adenosine
22. BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport
23. Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo
24. Circumvention of adriamycin resistance by dipyridamole analogues: A structure-activity relationship study
25. Dipyridamole-mediated reversal of multidrug resistance in MRP over-expressing human lung carcinoma cells in vitro
26. P-glycoproteins and multidrug resistance
27. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene
28. Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug
29. Adriamycin resistance in HL-60 cells in the absence of detectable P-glycoprotein
30. Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells
31. Mechanisms of multidrug resistance in HL60 cells: Analysis of resistance associated membrane proteins and levels of mdr gene expression
32. Mechanisms of multidrug resistance in HL60 cells: Detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein
33. +-adenosine triphosphatase activity in multidrug resistance in HL60 cells
34. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein
35. Triptycenes: A novel synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, induce DNA cleavage and decrease the viability of leukemic cells in the nanomolar range in vitro
36. Tricyclic pyrone analogs: A new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo
37. Quinone isomers of the WS-5995 antibiotics: Synthetic antitumor agents that inhibit macromolecule synthesis, block nucleoside transport, induce DNA fragmentation and decrease the growth and viability of L1210 leukemic cells more effectively than ellagic acid and genistein in vitro
38. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture
39. S-phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine
40. Cytochalasin B induces cellular DNA fragmentation
41. Structure-antitumor activity relationships among quinone derivatives
42. Anthraquinone anticancer agents
43. Antiproliferative effects of compounds derived from plants of northeast Brazil
44. Oncocalyxones A and C, 1,4-anthracenediones from Auxemma oncocalyx: Comparison with anticancer 1,9-anthracenediones
45. Antineoplastic agents. Structure-activity relationship study of bis (substituted aminoalkylamino) anthraquinones
46. Aloe-emodin is a new type of anticancer agent with selective activity against neuroectodermal tumors
47. Cytotoxicity, redox cycling and photodynamic action of two naturally occurring quinones
48. Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: Novel inhibitors of protein kinases
49. Acute toxicity to Selenastrum capricomutum of aromatic compounds from coal conversion
50. Production of anthraquinones and their effect on the life of the environment
51. Quinone-induced toxicity to Tetrahymena: Structure-activity relationships
52. Quenching of chlorophyll fluorescence by substituted anthraquinones
53. NCI's anticancer drug screening program may not be selecting for clinically active compounds
54. Resistance of mammalian tumor cells to inhibitors of DNA topoismomerase
55. DNA repair: Enzymatic mechanisms and relevance to drug response
56. Glutathione-associated enzymes in anticancer drug resistance
57. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
58. Cellular resistance to topoisomerase targeted drugs: From drug uptake to cell death
59. Contribution of the nucleoside transport system to doxorubicin transport in HL60 cells but not in mononuclear cells